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Abstract Genetic research gained new momentum with
the completion of the Human Genome Project in 2003. For-
merly centered on the investigation of single-gene disor-
ders, genetic research is increasingly targeting common
complex diseases and in doing so is studying the whole
genome, the environment and its impact on genomic varia-
tion. Consequently, biobanking initiatives have emerged
around the world as a tool to sustain such progress.
Whether they are small scale or longitudinal, public or pri-
vate, commercial or non-commercial, biobanks should con-
sider the possibility of closure. Interestingly, while raising
important ethical issues, this topic has hardly been explored
in the literature. Indeed, ethical issues associated with sale,
insolvency, end of funding, or transfer of materials to other
entities (which are all issues either related to or possible
consequences of closure) are seldom the subject of discus-
sion. In an attempt to Wll this gap, this paper will discuss—
using population and direct-to-consumer (DTC) genetic
testing companies’ biobanks as case studies—(1) interna-
tional and national normative documents addressing the
issue of closure and (2) the internal policies of population
biobanks and DTC genetic testing companies. The analysis
will inform the debate on biobank closure and elucidate the
underlying ethical issues, which include, but are not limited
to informed consent, storage and privacy.
Introduction
Since their creation, biobanks have been credited for facili-
tating human genetic research. Recently, biobanks have
included studies aiming to examine and understand dis-
eases by analyzing genetic variation and gene–environment
interactions in the general population (Thorisson et al.
2009). Today, biobankers constantly stress the need to col-
lect larger numbers of samples and data over time, so as to
achieve statistical signiWcance (Burton et al. 2009). This
“constant need” has ampliWed the important weight of
already existing collections.
However, the statistical power of a collection is not the
only factor that guarantees sustainability. Indeed, bio-
banks—deWned as “an organized collection of human bio-
logical material and associated information stored for one
or more research purposes” (P3G 2009)—depend on the
availability of funding. This reality should theoretically,
and from a purely managerial perspective, prompt biobanks
to consider the potential and eventual end of their opera-
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426 Hum Genet (2011) 130:425–432tions. More particularly, what will happen to biological
materials upon closure, whether unexpected or planned?
Will the data and the samples be destroyed or will they be
transferred to another entity? If transferred, what are the
criteria that will need to be met before such transfer? What
should participants be made aware of in the consent process
with regard to closure of the biobank?
In order to assess these matters from across the public–
private spectrum, population biobanks and direct-to-con-
sumer (DTC) genetic testing companies are analyzed here
as case studies. It is apparent that very little has been writ-
ten on the ethical, legal and social issues of biobank clo-
sure. For population biobanks, the only publications on this
issue pertain to a particular legal jurisdiction (Janger 2005;
Rothstein 2005) or remain general in scope (Robertson
2003). Generally, any potential dissolution of a biobank
should be addressed in the consent forms (Robertson 2003).
Moreover, “bank organizers and their institutional aYliates
have ‘moral’ duties not to waste those eVorts by dissolving
those banks without arranging for transfer of materials to
new research entities” (Robertson 2003). No further discus-
sion is provided on these moral duties or the underlying
ethical or legal principles associated therewith.
Similarly, the ending of operations of companies that
sell DTC genetic testing and that also bank client data
(Howard et al. 2010) also raises similar questions. For
example, what will happen to the genomic data and sam-
ples that are held by the company if the latter goes bankrupt
or is sold to another entity? There are imminent reasons for
concern. In November 2009, the biotech company deCODE
Genetics, which markets the genetic service called deCO-
DEme, Wled a voluntary petition for relief under Chapter 11
of the U.S.A. Bankruptcy Code. Furthermore, there is no
academic literature addressing the topic of closure for DTC
genetic testing companies.
In order to address the issue of closure in the context of
population biobanking and DTC genetic testing companies,
this article Wrst discusses international and national norma-
tive documents (Centre of Genomics and Policy 2011
HumGen International Database). Second, this article will
provide some examples from population biobanks and DTC
genetic testing companies on how their consent forms and
internal policies address closure. The result of these analy-
ses will inform further discussion on the underlying ethical
issues raised by biobank closures.
How do population biobanks address closure?
Population biobanks: governance
To further our understanding of common disease risk and
human health, population genomics draws on basic data on
genomic variation and on lifestyle behaviors and environ-
mental factors (Khoury 2004). But the study of normal
genomic variation across whole populations requires the
collection of data and biological samples from individuals
on a longitudinal scale (Khoury 2004; Knoppers and
Abdul-Rahman (Zawati) 2008). Accordingly, large-scale
population biobanking initiatives have thrived around the
world. As for their characterization, population biobanks
have been deWned as:
“a collection of biological materials that has the fol-
lowing characteristics: (i) the collection has a popula-
tion basis; (ii) it is established, or has been converted,
to supply biological materials or data derived there-
from for multiple future research projects; (iii) it con-
tains biological materials and associated personal
data, which may include or be linked to genealogical,
medical and lifestyle data and which may be regularly
updated; (iv) it receives and supplies materials in an
organized manner” (Council of Europe 2006).
In fact, the level of organization of population biobanks
is crucial to their long-term sustainability. Such organiza-
tion generally implies the existence of consent procedures
for recruitment, access mechanisms for national and inter-
national collaborations and management policies for inter-
nal procedural arrangements.
With respect to governance, we can diVerentiate
between two general types of biobanks: “legislatively regu-
lated” and “self-regulated” (Cutter et al. 2004). The former
are created following the adoption of a legal instrument
delineating their use, structure and operation (Cutter et al.
2004). These instruments usually take the form of laws or
regulations and are either biobank-speciWc or general (i.e.
largely governing genetic research that collects samples
and data). As for “self-regulated” biobanks, their use, struc-
ture and operations usually follow non-binding normative
documents, such as guidelines, opinions and statements
(Cutter et al. 2004).
Population biobanks: legislation and closure
Using the HumGen International Database, we retrieved
biobank legislation addressing the issue of closure from
Iceland, Sweden and Norway.
Iceland’s Biobanks Act of 2000 (Government of Iceland
2000) was the Wrst piece of European legislation speciW-
cally dealing with biobanks. The Act states that in order to
establish a biobank, a licence must be granted by the Minis-
ter of Health following the receipt of recommendations
from the Medical Director of Health and the National Bio-
ethics Committee. The only mention of closure in this law
relates to the preservation of biological samples. Indeed, it
asserts that if the licensee decides to cease operations of the123
Hum Genet (2011) 130:425–432 427biobank or “should the licence have been revoked […] the
Minister shall, after receiving recommendations […] make
a decision on the disposal of the biobank, taking into
account the wishes and proposals of the licensee” (Govern-
ment of Iceland 2000). Moreover, the Act also mentions the
possibility of closure as a punitive measure. It states that if
“the licensee or its employees violate the terms of the Act or
government directives on the basis of the Act, […] the con-
ditions of the licence are not fulWlled, or if the licensee
proves unable to operate the biobank”, the Minister could
revoke the licence provided under the terms of this Act.
Two types of revocation are mentioned: one which allows
“a reasonable period of grace to rectify matters” (Govern-
ment of Iceland 2000) and another that is more abrupt,
without notiWcation or possibility for rectiWcation. The Bio-
banks Act mentions no ethical or legal issues relating to the
end of operations nor does it set—as a precondition to the
licence—the existence of a plan for closure.
Norway’s 2003 Act Relating to Biobanks (Government
of Norway 2003) does, however, request such a plan to
establish a research biobank. The researcher must provide
the regional committee for medical research ethics a notiW-
cation containing various information, including “the
length of time for which the biobank is to be maintained
and what will be done with the material when it is closed
down”. This notiWcation will also be considered by the
Ministry in question in the Act and if the information pro-
vided does not satisfy ethical considerations or important
societal interests, the biobank may not be established. The
Act does not specify the scope of such ethical consider-
ations or nature of these social interests. It does mention,
however, that the Ministry might decide, if closure is inevi-
table, to maintain the biobank or transfer its material to
another biobank, given the importance of its contents.
Another example of a law that discusses closure is Swe-
den’s Biobanks in Medical Care Act of 2003 (Government
of Sweden 2003). Yet, this legislation only mentions that if
the materials of a biobank are no longer signiWcant for its
agreed purpose and where there is no public interest to
maintain its specimens, the biobank could close down and
its specimens destroyed or returned to the care provider.
There is no mention of any requirement for a closure plan
or on the need to disclose such a possibility to the partici-
pants during consent procedures.
In 2010, the Swedish Ministry of Health and Social
AVairs formulated proposals for the amendment of the
2003 Act and published its Inquiry’s propositions in a
Report entitled A New Biobanks Act (Government of Swe-
den 2010). In the latter, the Inquiry “considers that permis-
sion from the National Board of Health and Welfare is to be
required before a biobank or tissue samples may be trans-
ferred to another principal. Special grounds will still be
required before granting permission for a transfer” (Gov-
ernment of Sweden 2010). Moreover, “the Inquiry proposes
that when assessing whether or not there are special
grounds for a transfer, the extent to which the donor’s inter-
ests can be upheld following the transfer are to be consid-
ered” (Government of Sweden 2010).
Finally, the Council of Europe’s Recommendation Rec
(2006)4 of the Committee of Ministers to Member States on
Research on Biological Materials of Human Origin men-
tions only that speciWc procedures must be in place for the
transfer or the closing of a population biobank (Council of
Europe 2006). There is no mention whatsoever of the
underlying ethical or legal concerns with such transfer or
closure and whether any plan should be disclosed to pro-
spective participants.
Population biobanks: guidelines and closure
The most signiWcant international guidance on the issue of
biobanks closure is found in the Organisation for Economic
Co-operation and Development (OECD)’s 2009 Guidelines
on Human Biobanks and Genetic Research Databases
(Organisation for Economic Co-operation and Develop-
ment 2009). Reserving a distinct section on the “Discontin-
uation of the Human Biobanks and Genetic Research
Databases (HBGRD) and disposal of materials and data”,
the OECD’s Guidelines state that biobanks should develop
a plan for unexpected discontinuations. They mention the
termination of funding and the lack of scientiWc purposive-
ness as possible reasons for discontinuation.
Moreover, the Guidelines state that researchers must
develop “plans for the appropriate transfer, disposition and
destruction of human biological materials and data” (Orga-
nisation for Economic Co-operation and Development
2009), which shall be done in accordance with the research
protocol, legislation and regulation and the participant’s
informed consent (Organisation for Economic Co-opera-
tion and Development 2009). On that particular issue, the
OECD Guidelines present an interesting approach in the
event that biobanks have no other choice but to close down.
They state that the operators of such a biobank should
indeed “consider the transfer of its resources to another
entity” (Organisation for Economic Co-operation and
Development 2009). Just like Norway’s Act Relating to
Biobanks, the OECD guidelines emphasize the need to
maximize the use of the participants’ data and samples. It,
however, adds an interesting condition to such transfer:
“the operators should ensure that the recipient has in place
equivalent policies, governance structure, equipment and
systems, and staV” (Organisation for Economic Co-opera-
tion and Development 2009).
The German National Ethics Council’s 2004 Biobanks
for Research document serves as an example of a national
normative document addressing the issue of closure. It123
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adhere to what’s stated in the participants’ consent form.
The German document states that the information con-
tained in the consent form should extend to biobank closure
and to the possibility of transferring the biobank as a whole
to a third party for the sake of minimizing the loss of “valu-
able potential research material”. Moreover, the National
Ethics Council provides that in the absence of participants’
consent on the issue, such transfer is acceptable if the data
and samples are anonymized and if they are transferred to
an equivalent institution (university to university and com-
mercial sector to commercial sector). It does not request,
however, that biobanks ensure that the third party abide by
the same policies, as the OECD Guidelines demand. The
Council’s 2010 Human Biobanks for Research (German
National Ethics Council 2010) does not provide further
guidance on the issue.
Population biobanks and closure: current practices
Having reviewed the existing legislative and self-regulatory
normative documents on the topic of biobank closure, we
deemed it important to assess how population biobanks
addressed the topic in their internal policies. The consent
forms and access and management policies of 28 popula-
tion biobanks were reviewed. Our review was limited by
several factors, namely the language barrier, the fact that
some documentation is currently unavailable, and the fact
that some biobank websites do not provide public access to
their policies. Nonetheless, the following examples serve to
illustrate the current strategies of population biobanks on
closure.
CARTaGENE, a Quebec-based population biobank
resource, states in its Management Policy (CARTaGENE
2009) that it “will keep operating as long as its funding
allows for the continuation of its activities, its objectives set
at the time it was created and until suYcient robust mea-
sures to ensure the conWdentiality of CARTaGENE’s con-
tents can be maintained” (CARTaGENE 2009). It speciWes
that the institutional review board of the host institution
may then authorize the destruction or the transfer of data
and samples to another trustee. There is no mention of the
need to ensure that the other institutional trustee has equiv-
alent policies, governance structure, equipment and sys-
tems or staV.
Another example of a biobank that has tackled the issue
of ending of operations in length is LifeGene—a Swedish
population biobank. Its Ethics Policy (LifeGene 2009) doc-
ument speciWes that:
“LifeGene will have a detailed strategy for handling
contingencies in the event that LifeGene has to close
or make other substantial transitions in the holdings
or control of the resource. This will address the possi-
bility of partial or full transfer of the resource,
whether elective or as a result of insolvent liquidation.
The objective is to ensure that the protection and
respect for the rights of the participants provided by
this Ethics Policy document continue to be main-
tained. Information about such measures will be made
available to participants” (LifeGene 2009).
As for the UK Biobank, its Ethics and Governance
Framework states that a detailed strategy will be developed
for handling “contingencies in the event that the UK Bio-
bank charitable company has to close or make other sub-
stantial transitions in the holdings or control of the
resource.” According to the Framework, “the objective will
be to ensure that the protection and respect for the rights of
the participants provided by this Framework continue to be
maintained […]” (UK Biobank 2006). Lastly, it highlights
that information about any measures planned for such
events will be made available to participants.
“Biobanking” by DTC genetic testing companies: 
how is closure addressed?
DTC genetic testing and biobanking
The term DTC genetic testing has been described as either
the marketing and/or the oVer of genetic tests directly to
the public without an intermediate health care professional
(Genetics and Public Policy Center 2006; Mitchell et al.
2010). One type of service oVered by some DTC genetic
testing companies is known as full genome testing (How-
ard et al. 2010) or genome scanning (McGowan et al.
2010) or genome-wide-testing (GWT). Such testing
involves the genotyping of hundreds of thousands to mil-
lions of genetic markers (often single nucleotide polymor-
phisms, SNPs) throughout the genome. Although this
amount of data is not equivalent to that produced by
sequencing the entire genome (approximately 3 billion
data points), it still involves a great deal of data that can
easily fuel numerous genomic studies in the immediate-
and medium-term future. Many of the DTC genetic testing
companies performing GWT destroy both the saliva and
DNA samples of consumers but retain the data generated
for further research (Howard et al. 2010). As such, they
can be considered data repositories. These (mostly private)
companies were not necessarily included in the traditional
deWnition of biobanks. We include them here as they are
nevertheless genetic data repositories accessed by diVerent
entities conducting genetic and genomic research (Howard
et al. 2010). Therefore, as in the case for traditional bio-
banks, the (lack of) established provisions for the closure123
Hum Genet (2011) 130:425–432 429or sale of a DTC genetic testing company also raises ethi-
cal issues.
Normative documents regarding DTC genetic testing 
companies and closure
The 19 normative documents regarding DTC genetic test-
ing found in the “Guidelines, Laws and Policies” section of
the DTCgen module of the HumGen International Database
(Centre of Genomics and Policy DTCGen 2011) were scru-
tinized for information on the closure of a DTC genetic
testing company. Of the 19 normative documents studied,
only 4 addressed the issue of closure (Table 1). That being
said, the statements made are relatively vague and do not
discuss the issue in any great depth. The Secretary’s Advi-
sory Committee on Genetics, Health and Society merely
mentions the issue in passing. Meanwhile, the European
Society of Human Genetics (ESHG) statement and the
NuYeld Council Report from the United Kingdom are a bit
more speciWc but remain brief. The ESHG maintains that:
“companies oVering DTC genetic tests should… have a
clearly laid out plan as to what will happen to the samples
and data should the company be sold or go bankrupt”
(ESHG 2010). The NuYeld Council states: “We recom-
mend that all companies that provide genetic analysis for
susceptibility to common multifactorial diseases should
make… arrangements for data security (including in case of
any changes to the administration of the company)”.
Finally, the Human Genetics Commission’s 2010 Common
Framework of Principles for Direct-to-Consumer Genetic
Testing Services is more speciWc and pointed with its rec-
ommendations but still falls short of providing an elaborate
“how-to” guide for companies. While personal and genetic
data are to be disposed of securely or transferred under the
same terms of consent originally provided by the consumer,
the Principles fail to mention how this would be enforced
or controlled between companies.
DTC genetic testing companies and closure: current 
practices
We also studied the websites (including consent forms, pri-
vacy policies, terms of use, and service agreements) of four
DTC companies oVering GWT in order to retrieve informa-
tion regarding the end of operations (Table 2). Namely, we
studied the websites of the companies 23andMe, deCODE
(for the service deCODEme), Navigenics and Pathway
Genomics. Although there are many more companies
which sell genetic testing services DTC, these four compa-
nies sell GWT (as opposed to single-gene or multi-gene
testing), are relatively well known, and perform some form
of research with consumer data (Howard et al. 2010;
Pathway Genomics 2010).
All four companies do mention the possibility of a
merger or acquisition (Table 2). Three of the companies
(23andMe, deCODE and Pathway Genomics) explicitly
state that in the event of a merger or acquisition the acquir-
ing company would have to comply with the provisions of
the existing privacy statements. However, none of the com-
panies appear to address the issue of closure in-depth, espe-
cially not vis-à-vis information for consumers.
Discussion
An important and obvious conclusion from the above is that
there is a dearth of information available on both popula-
tion and DTC genetic testing company biobank closure.
Indeed, the earliest mention of closure in normative docu-
ments governing population studies is from Iceland’s Bio-
banks Act of 2000, while in-depth discussion is found in the
OECD’s 2009 Guidelines (Organisation for Economic Co-
operation and Development 2009). The same could be said
about DTC genetic testing companies.
Although striking, one could argue that this scarcity is
somewhat comprehensible. Most of these population bio-
banks are relatively new and are still working on their
recruiting and seeking long-term sustainability. Moreover,
issues such as consent, conWdentiality, access and interna-
tional collaboration (Zawati et al. 2011; Knoppers 2010)
have been prioritized over speciWc procedures associated
with closure of particular biobanks. Although understand-
able, it is still a concern given that biobanks and DTC
genetic testing companies have been actively recruiting
participants/consumers. Furthermore, as has been shown by
the recent closure of onCore UK and the UK Human Tissue
Bank, biobanks are not immune to termination (Stephens
2011).
As for the documents discussing closure, emphasis was
put on the issue of disclosing the biobanks’ plans during
the initial consent process. Although not mentioned in
laws and regulations, this issue is embedded in self-
regulatory policies and guidelines, such as the German
National Ethics Council’s 2004 Biobanks for Research
document, the OECD’s Guidelines on HBGRDs and the
internal policies of some population and DTC genetic
testing biobanks. That being said, the fact that not all of
the biobanks reviewed mention their plans for closure in
the initial consent documentation could be problematic in
the long run since most guidelines discussing consent
highlight the importance of providing the participants
with the necessary information on storage of both their
data and samples (Council for International Organizations
of Medical Science 2002; European Society of Human
Genetics 2003; Organisation for Economic Co-operation
and Development 2009).123
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Normative document 
(organization, year)
Portion of documents addressing end of operations of 
companies selling genetic testing directly to consumers
A Common Framework 
of Principles for Direct-to 
Consumer Genetic Testing 
Services (Human Genetics 
Commission, 2010)
“4.1 The test provider should supply easily understood, accurate, appropriate and adequate information, 
which is also available in accessible formats, to consumers before obtaining consent for a genetic test. The 
following should be provided:
–information about what will happen to consumers’ biological samples, and personal and genetic data, if 
the company ceases trading.”
“7.4 If a test provider ceases trading, they should dispose of personal and genetic data securely or provide 
for transfer of responsibilities in accordance with the terms of consent given by the consumer.”
“8.1 The use, storage, transfer and disposal of biological samples provided for genetic testing should be 
carried out in accordance with applicable legal, ethical and professional standards. The nature, purpose and 
maximum duration of the storage should be speciWed.”
“8.3 If a test provider ceases trading, they should dispose of consumers’ biological samples securely or pro-
vide for transfer of responsibilities in accordance with the terms of consent given by the consumer.”
Direct-to-Consumer Genetic 
Testing—Report of the 
Secretary’s Advisory 
Committee on Genetics, 
Health, and Society 
(SACGHS, 2010)
Privacy protections
“Gurwitz and Bregman-Eschet explain that privacy interests also can be compromised if a genetic testing 
company decides to sell its database containing the genotypic and phenotypic information of its customers 
to a third party. For commercial biotechnology companies, databases that contain genetic information are 
some of their most valuable assets. A company might sell its database in case of Wnancial diYculty or sim-
ply for the sake of making a proWt, just as it might do with any other valuable asset. Many consumers may 
be unaware of this possibility. In the absence of a Federal law prohibiting the sale of personal genetic infor-
mation and in view of previous court decisions allowing the transfer of personal information from one en-
tity to another, the unrestricted sale or transfer of genetic information to a third party may be a real 
possibility. In such cases, personal information might be transferred to a company with less strict privacy 
protection mechanisms. This issue also raises the question of ownership of genotypic and phenotypic infor-
mation stored in the database. Who owns the information?”
“If a specimen and information retrieved from it are considered the property of the company collecting and 
storing it, then the company is free to treat it as any other commodity, including selling or transferring the 
information to a third party. One possible solution, as described by WinickoV and WinickoV, is to deWne 
the holder of genetic information as the “trustee” of the information it holds. This model would apply 
restrictions and responsibilities to the safekeeping of genetic information collected and stored by compa-
nies oVering DTC genetic tests. For example, it would place restrictions on the transferability of informa-
tion collected and future disclosures in the absence of consent from the customer.”
Medical ProWling and Online 
Medicine: the ethics of 
‘personalized healthcare’ 
in a consumer age 
(NuYeld Council 
on Bioethics, 2010)
Data protection
“9.23…Even if a company guaranteed security, if it went into administration or changed hands, there is no 
guarantee that the data held would be used for the same purposes for which it was originally gathered. For 
example, following the bankruptcy Wling of the company deCODE genetics in 2009 and the purchase of 
most of the assets by another organisation, it remains unclear what exactly will happen to the personal ge-
netic data held by deCODE genetics. Although the company has stated that the data will be used in the man-
ner that it was prior to their bankruptcy, it has been argued that deCODE’s new owners remain (legally) 
free to alter or expand their use of genetic data within a range of allowable uses.”
In Europe, if a company goes into administration or changes hands, the data should be used only in accor-
dance with the original consents or other lawfully authorized purposes. But this obligation does not apply 
to all jurisdictions and consumers may Wnd it diYcult to enforce even in Europe
…
9.51 We recommend that all companies that provide genetic analysis for susceptibility to common multi-
factorial diseases should make the following information prominently available in lay language for the con-
sumer before they buy:… arrangements for data security (including in case of any changes to the 
administration of the company).”
Statement of the ESHG on 
Direct-to-Consumer Genetic 
Testing for Health Purposes 
(European Society of 
Human Genetics, 2010)
Respect for private life
“Any genetic test should always be performed with respect for private life. In particular, companies oVering 
DTC genetic tests should preserve the customer’s privacy, keep their data conWdential, inform them about 
their security procedures, explain what will happen to the sample and the data when the testing process is 
concluded, and have a clearly laid-out plan as to what will happen to the samples and data should the com-
pany be sold or go bankrupt. Privacy and conWdentiality of the results, as well as possible consequences 
related to their disclosure to third parties, such as insurance companies and employers, should be discussed, 
when appropriate, as well as the property of the biological material and its fate after the results are con-
Wrmed.”123
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cussing closure is the need to protect the privacy of partici-
pants when transferring data and samples. This is not only
mentioned in the OECD’s 2009 Guidelines—where the
transfer is conditional to the recipient having equivalent
governance and resources—but in some DTC genetic test-
ing companies’ internal policies, which stress the need to
honour the Privacy Statement or Policy following the trans-
fer of information. Some population biobanks state that
data and samples will be transferred to institutions that will
protect and respect the participants’ rights if closure occurs.
But again, the fact that such an approach is not omnipresent
in many population and DTC genetic testing biobanks’
internal policies could be viewed negatively, especially
with the growing challenges facing the protection of pri-
vacy in the genomics era (Church et al. 2009).
Additionally, the need to maximize the use of partici-
pant’s data and samples is another element present in some
of the documents analyzed above. This is clearly shown
in Norway’s 2003 Act Relating to Biobanks (Government
of Norway 2003) and the 2009 OECD Guidelines on
HBGRDs. Indeed, as previously mentioned, the need to col-
lect data and samples in some studies is crucial to achieve
statistical signiWcance, and hence, already existing collec-
tions have an important weight. Stemming from the emerg-
ing ethical trend of reciprocity, striving to realize the full
beneWt of research to which participants have given their
data and samples is considered by some as an ethical imper-
ative, provided that conWdentiality is protected (European
Society of Human Genetics 2003).
In conclusion, there is a need for clearer institutional
frameworks on the issue of closure. In order to do that, nor-
mative documents will need to be adopted to provide
eYcient guidance on the matter. For biobankers, the most
valuable asset is the trust of their participants in their
endeavors (Knoppers and Abdul-Rahman (Zawati) 2009), a
trust that requires the provision of all necessary information
during the consent process and the existence of reasonable
and adequate mechanisms to protect their privacy and the
security of their data and samples. Through more active
discussion on the issue of closure and transparency in their
internal policies and protocols, population biobanks and
Table 2 Information available on websites of companies selling DTC genome-wide-testing
Company 
name
Section of 
website
Information regarding closure
deCODE Terms of use “deCODE will not intentionally share your personal information with third parties without your express 
consent except (i) to contractors deCODE uses to support its business (e.g., fulWllment services, technical 
support, and delivery services), in which case deCODE will require such third parties to agree to treat such 
information in accordance with this Privacy Policy, (ii) in connection with the sale, assignment, or other 
transfer of the business of this Website to which the information relates, in which case deCODE will require 
any such buyer to agree to treat such information in accordance with this Privacy Policy, or (iii) where re-
quired by applicable laws, court orders, or government regulations.” (http://www.decodeme.com/terms-of-
use, accessed March 10, 2011)
23andMe Privacy 
statement
“Business transitions
In the event that 23andMe goes through a business transition such as a merger, acquisition by another com-
pany, or sale of all or a portion of its assets, your Personal Information will likely be among the assets trans-
ferred. In such a case, your information would remain subject to the promises made in any pre-existing 
Privacy Statement.”
(https://www.23andme.com/about/privacy/, accessed March 10, 2011)
Consent 
document
“Could my participation end without my consent?
The 23andWe study may be terminated without your consent. In the following cases, 23andMe will main-
tain your Genetic & Self-Reported Information according to the terms of our Privacy Statement.
Transfer of ownership. If 23andMe undergoes a business transition such as an acquisition or merger, the 
23andWe research study may be terminated. 23andMe will require an acquiring company or merger agree-
ment to uphold the material terms of our Privacy Statement.”
(https://www.23andme.com/about/consent/, accessed March 10, 2011)
Navigenics Privacy 
policy
“However, we will not, without your explicit consent, disclose or share personally identiWable information 
about you with third parties except as required to provide the services you have requested, in the event Nav-
igenics is acquired by or merges into another company, or as otherwise required by applicable law. We limit 
access to Your Account Information and other personally identiWable information about you to appropriate 
Navigenics personnel on a need-to-know basis.” (http://www.navigenics.com/visitor/what_we_offer/
our_policies/privacy/, accessed March 10, 2011)
Pathway 
genomics
Privacy 
statement
“If Pathway enters into a business transaction, such as a merger, acquisition by another company, selling 
some or all of its assets, or bankruptcy, your personal information will, in most instances, be part of the 
assets transferred. We will require the acquiring company to comply with the material provisions of the Full 
Privacy Statement upon entering into such business transaction.” (https://www.pathway.com/about-us/pri-
vacy-policy, accessed March 10, 2011)123
432 Hum Genet (2011) 130:425–432DTC companies will continue to uphold this trust; i.e., of
course, if they want to continue “reaping the beneWts that
should Xow from the coming revelations about the
genome” (Collins 2010) eVectively in the years to come.
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